

**Lynda J. Krasenbaum MSN, APRN, BC**

**CURRENT POSITIONS**

NEW YORK HEADACHE CENTER, New York, New York.  
Advanced Nurse Practitioner—Headache Specialist

COLUMBIA UNIVERSITY, New York, New York.  
Adjunct Assistant Professor of Clinical Nursing

**EDUCATION & TRAINING**

UNIVERSITY OF PENNSYLVANIA, Philadelphia, Pennsylvania  
Master of Science in Nursing and Adult Primary Care Nurse Practitioner  
Post-Master's Certificate in Teaching

JOHNS HOPKINS UNIVERSITY, Baltimore, Maryland  
Graduate Coursework

SYRACUSE UNIVERSITY, Syracuse, New York  
Bachelor of Science in Nursing with double major in Nursing and Psychology

**CERTIFICATIONS**

Nationally certified as an Adult Nurse Practitioner by ANCC.  
Currently state certified as an Adult Nurse Practitioner in New York and Massachusetts, and formerly  
in New Hampshire and Pennsylvania.

**PAST POSITIONS**

COLUMBIA UNIVERSITY HEADACHE CENTER, New York, New York.  
Advanced Nurse Practitioner—Section of Neurology

DARTMOUTH HITCHCOCK MEDICAL CENTER, Lebanon, New Hampshire.  
Advanced Nurse Practitioner—Section of Neurology

DARTMOUTH MEDICAL SCHOOL, Lebanon, New Hampshire.  
Instructor of Medicine

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, Pennsylvania.  
Advanced Practice Nurse--General and Intermediate Care Neuro Units

JOHNS HOPKINS HOSPITAL, Baltimore Maryland.  
Clinical Nurse--Neurosciences, Ortho-Spine, and Epilepsy Unit  
Clinical Nurse--Affective and Eating Disorder Unit  
Clinical Nurse--Cardiac Surgical Intensive Care Unit

## **GRANTS**

Ortho-McNeil Educational Grant: \$10,000

## **PROFESSIONAL LICENSES**

Currently licensed as an RN in New York and Massachusetts, and formerly in New Hampshire, Pennsylvania and Maryland.

## **PROFESSIONAL SOCIETIES**

Member of Sigma Theta Tau International.  
Member of American Nurses Association.  
Member of American Association of Nurse Practitioners.  
Member of The Nurse Practitioner Association of New York State.  
Member of American Association of Neuroscience Nurses.  
Member of IHS (International Headache Society).  
Member of AHS (American Headache Society).  
Current DEA# for prescription writing.

## **RELEVANT EXPERIENCE**

Involved in numerous speaking engagements sponsored by professional educational organizations and pharmaceutical companies which focus primarily on headache diagnosis, treatment and management practices.

CEU/CME granted engagements

National Headache Foundation (NHF) supported monograph—Improving Patient Care in Migraine: A CE Program for Nurse Practitioners (supported by an unrestricted educational grant from AstraZeneca)

National Headache Foundation (NHF) supported monograph—Case Studies in the Differential Diagnosis of Headaches: Migraines, Sinus Headaches and Episodic Tension-Type Headaches (supported by an unrestricted educational grant from GlaxoSmithKline)

Headache Mini-Fellowship by Columbia University College of Physicians and Surgeons—Nationwide (2003-2004-2005)

HCNE (Headache Consortium of New England) Annual Headache Conference in Stowe, VT;

DHMC (Dartmouth Hitchcock Medical Center) Headache Symposium, Lebanon, NH;

NPACE Regional Conference (Nurse Practitioner Associates for Continuing Education) in Nassau, Bahamas, Orlando, FL, Boston, MA and in Chicago, IL —2003, 2004, 2005, 2006

MUD Season Nursing Symposium (North Country Health Consortium) in North Conway, NH;

Quarterly NP meeting for the Greater Keene/Peterborough, NH area;

Dartmouth Hitchcock Medical Center Certified Neuroscience Registered Nurse (CNRN) preparatory course, Lebanon, NH;

Critical Care nursing course (Neuroscience focus) at the Hospital of the University of Pennsylvania, Philadelphia, PA.

Community speaking engagements on headache and migraines  
Guardian Life Insurance--Educational Program, New York, NY

TIAA-CREF Insurance--Educational Program, New York, NY

St. Joseph's Hospital--Educational Program in Nashua, NH

#### **CLINICAL INVESTIGATIONS**

A Prospective Randomized, Two-Arm Controlled, Double-Blind, Multicenter Study to evaluate whether PFO closure (with the Premere™ PFO Closure System) is safe and effective in reducing migraine frequency. In Association with Robert Sommer and Velocimed, Inc., d/b/a St. Jude Medical, Inc., November 2005 to Present.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Botox (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Prophylactic Treatment of Headaches in the Chronic Headache Population. In Association with Thomas N. Ward and Allergan, June 2001 to April 2003.

A Double-Blind, Placebo-Controlled, Three-Way Cross-Over Clinical Study to Assess the Safety and Efficacy of Two Dose Regimens of Frovatriptan, Compared with Placebo, in Preventing Menstrually-Associated Migraine (MAM) Headache. In Association with Thomas N. Ward and Vernalis Limited, June 2001 to April 2003.

An Open-Label Safety and Immunogenicity Study of Myobloc®, Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia. In Association with Thomas N. Ward and Elan Pharmaceuticals, Inc., April 2001 to April 2003.

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan (ZOMIG®) 5-mg Orally Disintegrating Tablet in the Acute Treatment of Adult Subjects with Migraine Headache. In Association with Thomas N. Ward and AstraZeneca LP, December 2000 to April 2003.

A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Tolerability of the Zolmitriptan (ZOMIG®) 2.5-mg Orally Disintegrating Tablet When Taken As Soon As Possible after the Onset in the Acute Treatment of Migraine Headache. In Association with Thomas N. Ward and AstraZeneca LP, December 2000 to October 2001.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Attack Evaluation of Sumatriptan 50mg and 100mg versus placebo during a Migraine Headache at the first sign of pain. In Association with Thomas N. Ward and Glaxo Wellcome, Inc., August 2000 to January 2001.

An Open-Label Evaluation of the Long-Term Safety of Oral Naratriptan 1 Mg Twice Daily as Short-Term Prophylactic Treatment for Menstrually-Associated Migraine. In Association with Morris Levin and Glaxo Wellcome, Inc., February 2000 to July 2001.

An Open-label, Long-term Observational Study of the Safety and Tolerability of Sumatriptan Nasal Spray in the Treatment of Migraine in Adolescents. In Association with Thomas N. Ward and Glaxo Wellcome, Inc., May 2000 to October 2001.